secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2026-08-06T12:03:06+00:00
Accession:  0001600620-26-000059
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia Q2 2026 revenue up 19% to $83.2M; net income $37.4M, EPS $0.28
----------------------------------------------------------------------

- Total revenue $83.2M (+19% YoY); LUPKYNIS net product sales $79.4M (+19% YoY).
- Net income $37.4M (+74% YoY); diluted EPS $0.28 (+75% YoY).
- Cash from operations $52.5M; cash position $443.1M at June 30, 2026.
- Reiterated 2026 total revenue guidance $315M-$325M (11-15% growth).
- Initiated PRESERVE Phase 4 study combining LUPKYNIS with biologics; aritinercept in four indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062026000059/0001600620-26-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062026000059/auph-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001600620-26-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer